Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Pliant Therapeutics, Inc. on June 5, 2025. The filing details the approval of corporate governance amendments and the election of directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes and Voting Results
As of the record date (April 9, 2025), there were 61,386,278 shares of common stock outstanding. Stockholders approved four key proposals:
- Proposal 1 (Director Election): Elected John Curnutte, M.D., Ph.D., Katharine Knobil, M.D., and Thomas McCourt as Class II directors.
- Proposal 2 (Executive Compensation): Approved the non-binding advisory vote on named executive officer compensation.
- Proposal 3 (Liability Limitation): Approved an amendment to the Amended and Restated Certificate of Incorporation to limit the liability of certain officers under Delaware law. This became effective on June 9, 2025.
- Proposal 4 (Auditor Ratification): Ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The primary contingency noted is the effective date of the Certificate of Amendment, which was filed with the Delaware Secretary of State on June 9, 2025.
Investor Verification Checklist
- Verify the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific scope of officer liability limitations.
- Review the Definitive Proxy Statement filed on April 23, 2025, for detailed background on the director nominees and executive compensation.
- Confirm the final vote counts for the director elections, noting the significant number of broker non-votes (12,346,970 shares) for Proposals 1, 2, and 3.